ESMO 2024 | Evaluating the potential for nivolumab to extend survival in non-metastatic MIBC
Andromachi Kougioumtzopoulou
• 16 Sep 2024
Andromachi Kougioumtzopoulou, MD, MSc, National and Kapodistrian University of Athens School of Medicine, Athens, Greece, explores the potential of nivolumab to improve overall survival in non-metastatic muscle-invasive bladder cancer (nmMIBC) when added to standard chemoradiotherapy (CRT). Preliminary results in a Phase II trial (NCT03993249) indicate promising survival benefits, but additional Phase III data is needed to consider a shift in clinical practice. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
